Crystal forms of a pyridazinone trpc inhibitor
AssigneeGoldfinch Bio, Inc.
InventorsWenfeng Xue, Yuejun Gao
Life of this patent
Estimating the term…
Abstract
Disclosed are crystalline forms of Compound 100. In some embodiments, a crystalline form of Compound 100 has characteristic peaks in the XRPD pattern as shown in any one of FIGS. 1A, 2A, 3A, 4A, 5A, and 6A.
Claims59
A crystalline form of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one selected from:
- a. form A, characterized by X-ray powder diffraction peaks at 2Θ angles of 4.43±0.2°, 11.69±0.2°, 17.75±0.2° and 27.58±0.2°, wherein the characterized peaks are the highest peaks observed;
- b. form E, characterized by X-ray powder diffraction peaks at 2Θ angles of 11.71±0.2°, 15.24±0.2°, 24.79±0.2°, and 26.15±0.2°, wherein the characterized peaks are the highest peaks observed;
- c. form G, characterized by X-ray powder diffraction peaks at 2Θ angles of 15.34±0.2°, 24.58±0.2°, and 25.86±0.2°, wherein the characterized peaks are the highest peaks observed;
- d. form H, characterized by X-ray powder diffraction peaks at 2Θ angles of 13.79±0.2°, 23.61±0.2°, 27.10±0.2°, and 27.49±0.2°, wherein the characterized peaks are the highest peaks observed;
- e. form B, characterized by X-ray powder diffraction peaks at 2Θ angles of 4.40±0.2°, 17.48±0.2°, 17.72±0.2°, 18.46±0.2°, and 27.49±0.2°, wherein the characterized peaks are the highest peaks observed;
- and
- f. form C, characterized by X-ray powder diffraction peaks at 2Θ angles of 4.42±0.2°, 8.83±0.2°, 13.27±0.2°, and 17.72±0.2°, wherein the characterized peaks are the highest peaks observed.
A method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising combining a sample of crystalline form A, and a pharmaceutically acceptable excipient.
A method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one comprising the steps of:
- a. dissolving crystalline form A in a solvent to form a solution;
- and
- b. preparing the pharmaceutical composition from the solution.
A method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising combining a sample of crystalline form H and a pharmaceutically acceptable excipient.
A method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one comprising the steps of:
- a. dissolving crystalline form H in a solvent to form a solution;
- and
- b. preparing the pharmaceutical composition from the solution.
A method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising combining a sample of crystalline form E and a pharmaceutically acceptable excipient.
A method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one comprising the steps of:
- a. dissolving crystalline form E in a solvent to form a solution;
- and
- b. preparing the pharmaceutical composition from the solution.
A method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one, comprising combining a sample of crystalline form G and a pharmaceutically acceptable excipient.
A method of preparing a pharmaceutical composition of 4-chloro-5-(4-(4-fluoro-2-(trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)pyridazin-3(2H)-one comprising the steps of:
- a. dissolving crystalline form G in a solvent to form a solution;
- and
- b. preparing the pharmaceutical composition from the solution.
Dependencies are inferred from the claim text.